Retina/Vitreous News

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, discusses efficacy and safety data for the port delivery system ahead of its reintroduction.

PARK CITY, Utah — Stage one of the phase 3 DIAMOND trial of OCS-01, a high-concentration dexamethasone eye drop for diabetic macular edema, showed promising safety and efficacy outcomes. Stage two of the trial is underway.

A review of currently available data suggests that there is little or no difference in efficacy and safety between anti-VEGF biosimilars approved for neovascular age-related macular degeneration and their reference products.

DocGo and Spect have partnered to provide mobile health clinicians a more cost-effective way to screen patients at home for diabetic retinopathy and other eye diseases, according to a DocGo press release.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Carlos Quezada-Ruiz, MD, FASRS, of Genentech/Roche shares an update on Susvimo and the port delivery platform.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Doug Faunce, PhD, reviews AbbVie’s ongoing efforts in the eye care field.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Charles Semba, MD, chief medical officer of Eluminex Biosciences, discusses a trispecific antibody for refractory diabetic macular edema.

Melatonin use was associated with a decreased risk for both development and progression of age-related macular degeneration among adults aged 50 years or older, according to a study published in JAMA Ophthalmology.

The current prior authorization process required for anti-VEGF medications leads to treatment delays, increased health care costs due to administrative burdens and potentially worse visual outcomes.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Adam Turpcu, PhD, of Adverum Biotechnologies discusses Ixo-vec for neovascular age-related macular degeneration.